Nephros Inc.
NEPH | NASDAQ
$3.25
+$0.08 (+2.52%)
Nov 2, 2026, 12:30 PM ET · Market open
Company Profile
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Robert Banks | President, Chief Executive Officer & Director |
| Judy F. Krandel | Chief Financial Officer |
| Brianne McGuire | Director of Brand, Marketing & Business Development |
| Greg Lucas | President of Aether Water Systems |
| Judy Mazzini | Controller |
| Michael Milman | Vice President of R&D |
| Vashone R. Thomas | Vice President of Quality, Regulatory, & Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2026 | SC 13D/A | [Amend] Filing |
| Sep 16, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jun 12, 2026 | 4 | Filing |
| Jun 15, 2026 | 8-K | Current Report |
Nephros Inc.
| Country | United States |
| IPO Date | Sep 21, 2004 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Robert Banks |
Contact Details
380 Lackawanna Place South Orange,
New Jersey 07079 United States
Stock Details
| Ticker Symbol | NEPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001196298 |
| CUSIP Number | 640671400 |
| ISIN Number | US6406714005 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove NEPH